Skip to main content
. 2022 Jun 22;158(8):893–899. doi: 10.1001/jamadermatol.2022.2149

Figure 3. Serum Concentration of Rituximab (RTX) and Anti–Desmoglein 3 Antibody (DSG3 Ab) Serum Levels According to the Presence of Antirituximab Antibodies (ARAs) and Patients’ Clinical Courses.

Figure 3.

A, Serum concentration of RTX at month 14 (2 months after the first maintenance infusion of RTX at month 12) in relapsing patients with ARAs, nonrelapsing patients with ARAs, and patients without ARAs. B, Anti-DSG3 Ab serum level at month 18 in patients from the same subgroups. The positivity threshold for anti-DSG3 Abs is represented by the dotted line at 20 AU/mL.

aP < .05.

bP < .001.